Ma Liqiu, Li Yang, Sakamoto Yoshimitsu, Xie Lin, Suzuki Saaya, Yoshida Yukari, Sui Li, Guo Gang, Wen Jialing, Ren Wangcai, Kakimi Kazuhiro, Osada Kensuke, Takahashi Akihisa, Shimokawa Takashi
Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba 263-8555, Japan; Gunma University Heavy Ion Medical Center, Gunma 371-8511, Japan; Department of Nuclear Physics, China Institute of Atomic Energy, Beijing 102413, China.
Gunma University Heavy Ion Medical Center, Gunma 371-8511, Japan.
Neoplasia. 2025 Feb;60:101099. doi: 10.1016/j.neo.2024.101099. Epub 2024 Dec 13.
Although carbon-ion radiotherapy (CIRT) has led to good outcomes, controlling metastasis is still crucial for improving overall survival. This study aimed to evaluate the effectiveness of by two combinations, one of CIRT and anti-CTLA4 antibody, the other of CIRT and anti-PD-1 antibody, applied at different radiation doses for distal tumour and metastasis suppression.
Murine cancer cells (colon carcinoma Colon-26 cells for experiments and osteosarcoma LM8 cells for verification) were grafted into both sides of the hind legs of syngeneic mice. Right-side tumours were irradiated with 3 Gy or 10 Gy CIRT while the left-side tumours were not irradiated, followed by the administration of the anti-CTLA4 antibody or anti-PD-1 antibody. The diameter of the tumours in both legs was measured 3 times per week after irradiation. The number of pulmonary metastases was evaluated within 3 weeks after irradiation.
Compared with the control group, the high-dose group showed promising anti-cancer benefits in terms of both irradiated tumours and lung metastasis, but neither 10 Gy CIRT combined with the anti-CTLA4 antibody nor 10 Gy CIRT combined with the anti-PD-1 antibody suppressed the growth of distant unirradiated tumours. In the low-dose group, the effect on primary tumour control was slightly weaker than that in the high-dose treatment group, but significant suppressive effects on both distant unirradiated tumours and metastases were observed following 3 Gy CIRT combined with anti-CTLA4 antibody treatment. Specifically, the volume of distant unirradiated tumours decreased by 40 % compared with that of the control group, and no lung metastasis was observed.
Our findings suggest that there is an optimal dose range for the abscopal effect generated with the CIRT combined with anti-CTLA4 antibody, and it highlights a new opportunity for increased induction efficiency of the abscopal effect of combination therapy.
尽管碳离子放射疗法(CIRT)已取得良好疗效,但控制转移对于提高总生存率仍至关重要。本研究旨在评估CIRT与抗CTLA4抗体、CIRT与抗PD - 1抗体这两种组合在不同辐射剂量下对远端肿瘤和转移抑制的有效性。
将小鼠癌细胞(实验用结肠癌细胞Colon - 26和验证用骨肉瘤细胞LM8)接种到同基因小鼠的双侧后腿。右侧肿瘤接受3 Gy或10 Gy的CIRT照射,左侧肿瘤不照射,随后给予抗CTLA4抗体或抗PD - 1抗体。照射后每周测量两次双侧腿部肿瘤的直径。在照射后3周内评估肺转移灶的数量。
与对照组相比,高剂量组在照射肿瘤和肺转移方面均显示出良好的抗癌效果,但10 Gy的CIRT联合抗CTLA4抗体或10 Gy的CIRT联合抗PD - 1抗体均未抑制远处未照射肿瘤的生长。在低剂量组中,对原发肿瘤的控制效果略弱于高剂量治疗组,但3 Gy的CIRT联合抗CTLA4抗体治疗后,对远处未照射肿瘤和转移均观察到显著的抑制作用。具体而言,远处未照射肿瘤的体积与对照组相比减少了40%,且未观察到肺转移。
我们的研究结果表明,CIRT联合抗CTLA4抗体产生远隔效应存在一个最佳剂量范围,这为提高联合治疗远隔效应的诱导效率提供了新的契机。